Skip to content
Review

Yttrium-90 Radioembolization for High-Risk Hepatocellular Adenomas: A Single-Institution Experience.

Oct 2026 · Journal of Vascular and Interventional Radiology · pp. 109114 · 0 citations
Medicine

Abstract

Purpose

To evaluate the safety and efficacy of Yttrium-90 (Y-90) transarterial radioembolization (TARE) for the treatment of high-risk hepatocellular adenomas (HCAs) at a single tertiary care center.

Materials And Methods

A retrospective review was performed of all patients who underwent TARE for HCAs at a tertiary care center between 2010 and 2025. Clinical, laboratory, imaging, and safety data were collected for twelve patients with 22 HCAs included in the study. The primary endpoint was treatment-related adverse events (AEs) graded by CTCAE and SIR AE classification. The secondary endpoints included target and overall radiologic response assessed by mRECIST.1 Patients were followed up with MRI at 6 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months. Median follow-up between Y-90 and latest imaging was 17.7 months, with an IQR of 12.9 [8.0-20.9] months.

Results

Indications for treatment included symptomatic adenoma (5%, 1/22), risk of malignant transformation (100%, 22/22) and hemorrhage risk (50%, 11/22). Grade 1 AEs (nausea, fatigue, anorexia, diarrhea, abdominal and shoulder pain) occurred in 75% (9/12) of patients. No grade 2 or greater AEs occurred. The objective response rate (ORR) was 100% (20/20) (complete target lesion response [CR]: 85% (17/20), partial target lesion response [PR]: 15% (3/20)). No lesions ruptured, progressed, or recurred during follow-up.

Conclusion

In this single-institution experience, TARE was safe and demonstrated high short to intermediate-term ORRs in the treatment of high-risk hepatocellular adenomas. Larger prospective studies with longer duration of follow up are needed to confirm these findings.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.